Trevena CEO to Present at the Barclays Global Healthcare Conference

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company and leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 11, 2014 at 10:45 a.m. ET in Miami, FL.

To access a live audio webcast of the presentation, please visit the “Investors” section at www.trevenainc.com. The webcast will be archived for 90 days.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated biased ligand product candidates into the clinic – TRV027 to treat acute heart failure, TRV130 to treat moderate to severe acute pain intravenously, and TRV734 to treat moderate to severe acute and chronic pain orally. Trevena also plans to advance additional product candidates in its portfolio, including a preclinical program focused on central nervous system indications.

Investor Contacts:
Trevena, Inc.
Roberto Cuca, 610-354-8840 x224
Senior vice president and chief financial officer
rcuca@trevenainc.com
or
Argot Partners
Andrea Rabney, 212-600-1902
President and chief executive officer
andrea@argotpartners.com
or
Media Contact:
Argot Partners
Eliza Schleifstein, 917-763-8106
eliza@argotpartners.com

Source: Trevena, Inc.

Released March 5, 2014